Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Cancer Inform
2021 Jul 13;20:11769351211031864. doi: 10.1177/11769351211031864.
Show Gene links
Show Anatomy links
Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4).
Wargasetia TL
,
Ratnawati H
,
Widodo N
,
Widyananda MH
.
???displayArticle.abstract???
Breast cancer is the most common type of cancer in women globally. The overexpressed proteins, including EGFR, PI3K, AKT1, and CDK4, have a role in the growth of breast cancer cells. The 3D peptide structure of sea cucumber Cucumaria frondosa was modeled and then docked with EGFR, PI3K, AKT1, and CDK4 proteins using AutoDock Vina software. The docking result, which has the best binding affinity value, is continued with molecular dynamics simulation. The docking results showed that all peptides bind to the active sites of the four proteins. WPPNYQW and YDWRF peptides bind to proteins with lower binding affinity values than positive controls. The four proteins were in a stable state when complexed with the WPPNYQW peptide, which was seen from the RMSD and RMSF value. PI3K-YDWRF and AKT1-YDWRF complexes are stable, characterized by high RMSD values and increased volatility in several amino acids. WPPNYQW peptide has high potential as an antibreast cancer agent because it binds to the active sites of the four proteins with low binding affinity values and stable interactions. Meanwhile, the YDWRF peptide interacts with the four proteins with low binding affinity values, but the interaction is only stable on PI3K and AKT1 proteins.
Figure 1. All peptides bind to the active site of EGFR (A), PI3K (B), AKT1 (C), and CDK proteins (D). The active site of the protein is marked in yellow. The docking results showed that all peptides have potential as competitive inhibitors because they bind to the protein on the active site.AKT1 indicates Protein Kinase B1; CDK4, Cyclin Dependent Kinase 4; EGFR, Epidermal Growth Factor Receptor; PI3K, Phosphatidylinositol-3 kinase.
Figure 2. WPPNYQW (orange) and YDWRF (green) peptides bind to EGFR (A), PI3K (B), AKT1 (C), and CDK4 (D) on the same side as the inhibitor. WPPNYQW and YDWRF peptides have a similar binding mode to the inhibitor indicating the peptides have the potential to act as protein inhibitors.AKT1 indicates Protein Kinase B1; CDK4, Cyclin-Dependent Kinase 4; EGFR, Epidermal Growth Factor Receptor; PI3K, Phosphatidylinositol-3 kinase.
Figure 3. The stability of protein-ligand complex interactions can be seen from RMSD values. (A) The RMSD values of the EGFR-inhibitor, EGFR-WPPYQW, and EGFR-YDWRF complexes tend to be stable. (B) The RMSD values of the PI3K-inhibitor, PI3K-WPPYQW, and PI3K-YDWRF complexes are stable during the simulation. (C) The RMSD values of the AKT1-inhibitor, AKT1-WPPNYQW, and AKT1-YDWRF complexes are stable during the simulation. (D) The RMSD value of the CDK4-WPPNYQW complex is more stable than the CDK4-inhibitor and CDK4-YDWRF. The CDK4-YDWRF complex tends to be unstable because of its high RMSD value. (E) RMSD peptides and target proteins.AKT1 indicates Protein Kinase B1; CDK4, Cyclin-Dependent Kinase 4; EGFR, Epidermal Growth Factor Receptor; PI3K, Phosphatidylinositol-3 kinase; RMSD, root mean square deviation.
Figure 4. The stability of each amino acid residue during the simulation can be seen from the RMSF value. (A) Val1010 and Val1011 residues of the EGFR-YDWRF complex have high flexibility. (B and C) The residues on the PI3K-Ligands and AKT1-Ligands complexes tend to be stable during simulation. (D) Pro245, Arg246, Gly247, and Ala248 residues of the CDK4-YDWRF complex have high flexibility. High flexibility indicates instability of residue.AKT1 indicates Protein Kinase B1; CDK4, Cyclin-Dependent Kinase 4; EGFR, Epidermal Growth Factor Receptor; PI3âK, Phosphatidylinositol-3 kinase; RMSF, root mean square fluctuation.
Figure 5. The stability of the complex structure can be seen from the number of hydrogen bonds during the simulation. The number of hydrogen bonds in EGFR-peptides (A), PI3K-peptides (B), AKT1-peptides (C), and CDK4-peptides (D) were not significantly different from proteins-inhibitors. These results indicate the structural stability of the protein-peptide complexes.AKT1 indicates Protein Kinase B1; CDK4, Cyclin-Dependent Kinase 4; EGFR, Epidermal Growth Factor Receptor; PI3K, Phosphatidylinositol-3 kinase.
Figure 6. The molecular dynamic binding energy represents the stability of the protein-ligand interaction during the simulation. The more positive the molecular dynamic binding energy value, the more stable the protein-ligand interaction. The molecular dynamic binding energy values of EGFR-peptides (A), PI3K-peptides (B), AKT1-peptides (C), and CDK4-peptides were lower than proteins-inhibitors.AKT1 indicates Protein Kinase B1; CDK4, Cyclin-Dependent Kinase 4; EGFR, Epidermal Growth Factor Receptor; PI3K, Phosphatidylinositol-3 kinase.
Abliz,
Wortmannin, PI3K/Akt signaling pathway inhibitor, attenuates thyroid injury associated with severe acute pancreatitis in rats.
2015, Pubmed
Abliz,
Wortmannin, PI3K/Akt signaling pathway inhibitor, attenuates thyroid injury associated with severe acute pancreatitis in rats.
2015,
Pubmed
Al-Kuraya,
Prognostic relevance of gene amplifications and coamplifications in breast cancer.
2004,
Pubmed
Al Marzouqi,
Frondoside A inhibits human breast cancer cell survival, migration, invasion and the growth of breast tumor xenografts.
2011,
Pubmed
,
Echinobase
An,
Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.
1999,
Pubmed
Arteaga,
Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?
2004,
Pubmed
Aubry,
Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.
2006,
Pubmed
Bonelli,
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
2019,
Pubmed
Brehmer,
Cellular targets of gefitinib.
2005,
Pubmed
Brinckerhoff,
Interstitial collagenases as markers of tumor progression.
2000,
Pubmed
Chang,
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.
2003,
Pubmed
Chen,
Principal component analysis of binding energies for single-point mutants of hT2R16 bound to an agonist correlate with experimental mutant cell response.
2015,
Pubmed
Citri,
EGF-ERBB signalling: towards the systems level.
2006,
Pubmed
Corona,
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
2018,
Pubmed
Craik,
The future of peptide-based drugs.
2013,
Pubmed
Dallakyan,
Small-molecule library screening by docking with PyRx.
2015,
Pubmed
Day,
Crystal structure of human CDK4 in complex with a D-type cyclin.
2009,
Pubmed
Deeba,
Potential entry inhibitors of the envelope protein (E2) of Chikungunya virus: in silico structural modeling, docking and molecular dynamic studies.
2017,
Pubmed
DeSantis,
Breast cancer statistics, 2019.
2019,
Pubmed
Dubey,
Recent advances in protein-ligand interactions: molecular dynamics simulations and binding free energy.
2013,
Pubmed
Ghosh,
Identification of polyphenols from Broussonetia papyrifera as SARS CoV-2 main protease inhibitors using in silico docking and molecular dynamics simulation approaches.
2021,
Pubmed
Glaysher,
Targeting EGFR and PI3K pathways in ovarian cancer.
2013,
Pubmed
Hemmings,
PI3K-PKB/Akt pathway.
2012,
Pubmed
Huether,
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics.
2005,
Pubmed
Janakiram,
Sea Cucumbers Metabolites as Potent Anti-Cancer Agents.
2015,
Pubmed
,
Echinobase
Kang,
Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment.
2013,
Pubmed
Krieger,
New ways to boost molecular dynamics simulations.
2015,
Pubmed
Kunnimalaiyaan,
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
2006,
Pubmed
Kuo,
Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells.
2006,
Pubmed
Liao,
Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR).
2011,
Pubmed
Lin,
An ATP-site on-off switch that restricts phosphatase accessibility of Akt.
2012,
Pubmed
López-Knowles,
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
2010,
Pubmed
Luparello,
Cytotoxic Potential of the Coelomic Fluid Extracted from the Sea Cucumber Holothuria tubulosa against Triple-Negative MDA-MB231 Breast Cancer Cells.
2019,
Pubmed
,
Echinobase
Malumbres,
Cell cycle, CDKs and cancer: a changing paradigm.
2009,
Pubmed
Martínez,
Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis.
2015,
Pubmed
Mathur,
Cancer Statistics, 2020: Report From National Cancer Registry Programme, India.
2020,
Pubmed
Nitulescu,
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).
2016,
Pubmed
Otto,
Cell cycle proteins as promising targets in cancer therapy.
2017,
Pubmed
Pace,
Contribution of hydrogen bonds to protein stability.
2014,
Pubmed
Pao,
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
2005,
Pubmed
Pernas,
CDK4/6 inhibition in breast cancer: current practice and future directions.
2018,
Pubmed
Peurala,
The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer.
2013,
Pubmed
Pinkas,
MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition.
2002,
Pubmed
Rimawi,
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.
2010,
Pubmed
Rivera-Franco,
Delays in Breast Cancer Detection and Treatment in Developing Countries.
2018,
Pubmed
Schirrmacher,
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review).
2019,
Pubmed
Seydi,
Selective Toxicity of Persian Gulf Sea Cucumber (Holothuria parva) and Sponge (Haliclona oculata) Methanolic Extracts on Liver Mitochondria Isolated from an Animal Model of Hepatocellular Carcinoma.
2015,
Pubmed
,
Echinobase
Sherr,
Targeting CDK4 and CDK6: From Discovery to Therapy.
2016,
Pubmed
Song,
AKT as a Therapeutic Target for Cancer.
2019,
Pubmed
Tokunaga,
Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.
2006,
Pubmed
Trott,
AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.
2010,
Pubmed
Twombly,
Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
2005,
Pubmed
Wainberg,
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
2010,
Pubmed
Walker,
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.
2000,
Pubmed
Wargasetia,
Mechanisms of cancer cell killing by sea cucumber-derived compounds.
2017,
Pubmed
,
Echinobase
Wee,
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.
2017,
Pubmed
Weisner,
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.
2019,
Pubmed
Wood,
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
2004,
Pubmed
Woodworth,
Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment.
2005,
Pubmed
Yang,
Targeting PI3K in cancer: mechanisms and advances in clinical trials.
2019,
Pubmed
Yang,
The prognostic value of phosphorylated Akt in breast cancer: a systematic review.
2015,
Pubmed
Yu,
Requirement for CDK4 kinase function in breast cancer.
2006,
Pubmed
Yuan,
PI3K pathway alterations in cancer: variations on a theme.
2008,
Pubmed
Yuan,
Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway.
2019,
Pubmed
,
Echinobase
Yun,
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
2008,
Pubmed
Zhang,
Generation of antioxidative peptides from Atlantic sea cucumber using alcalase versus trypsin: In vitro activity, de novo sequencing, and in silico docking for in vivo function prediction.
2020,
Pubmed
,
Echinobase
Zhang,
Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases.
2020,
Pubmed
Zhang,
A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.
2016,
Pubmed
Zhao,
Molecular dynamics simulation reveals insights into the mechanism of unfolding by the A130T/V mutations within the MID1 zinc-binding Bbox1 domain.
2015,
Pubmed
Zhao,
Differential effects of sulfated triterpene glycosides, holothurin A1, and 24-dehydroechinoside A, on antimetastasic activity via regulation of the MMP-9 signal pathway.
2010,
Pubmed
,
Echinobase
Zwang,
Synergistic interactions with PI3K inhibition that induce apoptosis.
2017,
Pubmed